Machine learning identifies disease-specific signatures in organoids derived from schizophrenia and bipolar disorder patients.
Medtronic (NYSE: MDT) today announced study results backing its adaptive DBS algorithm for personalized therapy in Parkinson's.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback